Charles Schwab Investment Management Inc Macrogenics Inc Transaction History
Charles Schwab Investment Management Inc
- $601 Billion
- Q3 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Macrogenics Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 30,008 shares of MGNX stock, worth $46,212. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30,008
Previous 334,349
91.02%
Holding current value
$46,212
Previous $404,000
87.38%
% of portfolio
0.0%
Previous 0.0%
Shares
34 transactions
Others Institutions Holding MGNX
# of Institutions
112Shares Held
50MCall Options Held
65.5KPut Options Held
93.9K-
Bellevue Group Ag Kuesnacht, V89.92MShares$15.3 Million0.36% of portfolio
-
Armistice Capital, LLC New York, NY5.96MShares$9.18 Million0.16% of portfolio
-
Black Rock Inc. New York, NY5.4MShares$8.32 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$6.51 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.18MShares$4.89 Million0.23% of portfolio
About MACROGENICS INC
- Ticker MGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,458,800
- Market Cap $94.6M
- Description
- MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...